Treating Migraine in Children and Adolescents
- 1 January 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 175 (1), 102
- https://doi.org/10.1001/jamapediatrics.2020.2002
Abstract
To the Editor We read with interest the Editorial by Zernikow1 regarding the meta-analysis2 published in JAMA Pediatrics on pharmacologic migraine prevention in children and adolescents. As experts, we agree with Zernikow that “migraine is not just a headache”1 and thus struggle with the advice that the “…cornerstone of treatment… is pain education.”1 Rather, it is education based on the underlying problem, which is very rarely education just about pain. Moreover, we agree that “globally, migraine experts recommend the regular use of pharmacologic prophylactic treatment in childhood.”1 However, this is where our agreement ends.This publication has 4 references indexed in Scilit:
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine ProphylaxisJAMA Pediatrics, 2020
- Can We Really Stop Pediatric Migraine?JAMA Pediatrics, 2020
- Practice guideline update summary: Pharmacologic treatment for pediatric migraine preventionHeadache: The Journal of Head and Face Pain, 2019
- Trial of Amitriptyline, Topiramate, and Placebo for Pediatric MigraineThe New England Journal of Medicine, 2017